WOBURN, Mass., Feb. 07, 2025 (WORLD NEWSWIRE)– Replimune Group, Inc. REPL, a medical phase biotechnology business pioneering the advancement of unique oncolytic immunotherapies, today revealed the grant of incentive equity awards to freshly worked with non-executive staff members.
The Business given equity awards to 34 staff members as a product incentive to beginning their work with the Business. The incentive awards include non-qualified stock alternatives to acquire an aggregate of 58,240 shares of the Business’s typical stock and limited stock systems representing an aggregate of 116,680 shares of the Business’s typical stock. Each alternative has a workout rate of $ 14.25 per share, which amounts to the closing rate of the Business’s typical stock on February 5, 2025 ( the “Date of Grant”). Each alternative has a 10-year term and will vest over 4 years, with 25% of the hidden shares vesting on the 1 year anniversary of the Date of Grant, and the rest vesting in regular monthly installations for 3 years afterwards. The limited stock systems vest in around 4 equivalent yearly installations starting on February 15, 2026.
The previously mentioned incentive awards were authorized by the payment committee of the Business’s board of directors in dependence on the work incentive exception under Nasdaq Listing Guideline 5635( c)( 4 ). While the incentive awards were given beyond the Business’s 2018 Equity Reward Strategy, the awards will have terms constant with those stated under such strategy.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was established in 2015 with the objective to change cancer treatment by pioneering the advancement of unique oncolytic immunotherapies. Replimune’s exclusive RPx platform is based upon a powerful HSV-1 foundation planned to optimize immunogenic cell death and the induction of a systemic anti-tumor immune action. The RPx platform is developed to have a distinct double regional and systemic activity including direct selective virus-mediated killing of the growth leading to the release of growth obtained antigens and changing of the growth microenvironment to spark a strong and long lasting systemic action. The RPx item prospects are anticipated to be synergistic with the majority of developed and speculative cancer treatment methods, resulting in the flexibility to be established alone or integrated with a range of other treatment alternatives. To find out more, please visit www.replimune.com.
Financier Questions
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Questions
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
Market News and Data gave you by Benzinga APIs